This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Digging into the results from the P3 ALPHA trial of AstraZeneca's danicopan (ALXN2040) in patients with paroxysmal nocturnal hemoglobinuria who experience extravascular hemolysis

Ticker(s): AZN

Who's the expert?

Institution: Ochsner Medical Center

  • Board Certified Hematologist/Oncologist  at Oschner Medical Center with over 13 years of experience.
  • Treats 8-10 patients with PNH.
  • Research interest in multiple myeloma, acute lymphoblastic leukemia, and acute myeloid leukemia; Clinical specializes in cell therapy and stem cell transplant.

Interview Goal
On this call we will be digging in to AstraZeneca's danicopan, a first-in-class oral Factor D inhibitor and the results from the Phase III ALPHA trial in patients with paroxysmal nocturnal haemoglobinuria and extravascular hemolysis.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.